全文获取类型
收费全文 | 8266篇 |
免费 | 935篇 |
国内免费 | 234篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 472篇 |
妇产科学 | 98篇 |
基础医学 | 2028篇 |
口腔科学 | 122篇 |
临床医学 | 876篇 |
内科学 | 1640篇 |
皮肤病学 | 205篇 |
神经病学 | 268篇 |
特种医学 | 132篇 |
外科学 | 441篇 |
综合类 | 875篇 |
现状与发展 | 5篇 |
预防医学 | 1357篇 |
眼科学 | 104篇 |
药学 | 440篇 |
2篇 | |
中国医学 | 148篇 |
肿瘤学 | 195篇 |
出版年
2024年 | 12篇 |
2023年 | 120篇 |
2022年 | 253篇 |
2021年 | 337篇 |
2020年 | 309篇 |
2019年 | 354篇 |
2018年 | 276篇 |
2017年 | 290篇 |
2016年 | 287篇 |
2015年 | 310篇 |
2014年 | 510篇 |
2013年 | 624篇 |
2012年 | 468篇 |
2011年 | 567篇 |
2010年 | 452篇 |
2009年 | 458篇 |
2008年 | 365篇 |
2007年 | 426篇 |
2006年 | 386篇 |
2005年 | 289篇 |
2004年 | 256篇 |
2003年 | 217篇 |
2002年 | 170篇 |
2001年 | 154篇 |
2000年 | 129篇 |
1999年 | 120篇 |
1998年 | 115篇 |
1997年 | 128篇 |
1996年 | 118篇 |
1995年 | 114篇 |
1994年 | 127篇 |
1993年 | 98篇 |
1992年 | 95篇 |
1991年 | 86篇 |
1990年 | 70篇 |
1989年 | 72篇 |
1988年 | 69篇 |
1987年 | 38篇 |
1986年 | 21篇 |
1985年 | 40篇 |
1984年 | 22篇 |
1983年 | 11篇 |
1982年 | 17篇 |
1981年 | 14篇 |
1980年 | 11篇 |
1979年 | 4篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 7篇 |
1975年 | 2篇 |
排序方式: 共有9435条查询结果,搜索用时 15 毫秒
1.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(5):578-584
IntroductionThere is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammation of microcirculation.Patients and methodsObservational study with renal allograft recipients diagnosed with cAMR (n = 5) who had not submitted a response to traditional treatment based on the combination of plasma replacements, immunoglobulins, and rituximab. Patients were told to be treated with TCZ as compassionate use in six doses per month (8 mg/kg/month). Renal function, proteinuria, and the intensity of DSAs were monitored during follow-up.ResultsFive patients, average age 60 ± 13 years, three male and two retrasplants (cPRA average 55%) with preformed DSAs. Treatment with TCZ was initiated within 47 ± 52 days of biopsy. In two cases treatment was discontinued after the first dose, by severe bicitopenia with cytomegalovirus viremia and by graft failure, respectively. In the three patients who completed treatment, no stability of renal function (serum creatinine from 1.73 ± 0.70 to 2.04 ± 0.52 mg/dL, e-FGR 4 6 ± 15 to 36 ± 16 mL/min), showed increased proteinuria (3.2 ± 4.0 to 6.9 ± 11.0 g/g) and the intensity of DSAs maintain stable. No changes were observed in the degree of inflammation of microcirculation (g + pt 4.2 ± 0.8 vs. 4.3 ± 1.0) or in the degree of transplant glomerulopathy (cg 1.2 ± 0.4 vs. 1.8 ± 1.0).ConclusionsTCZ therapy does not appear to be effective in modifying the natural history of chronic active antibody-mediated rejection, does not improve the degree of inflammation of microcirculation and does not reduces the intensity of DSAs. 相似文献
2.
内脏利什曼病是全球被忽视的传染病之一,危害严重。而利什曼原虫-人类免疫缺陷病毒(human immunodeficiency virus,HIV)合并感染对流行地区造成的威胁更甚。利什曼原虫与HIV存在相互作用,合并感染者在临床表现、诊断及治疗方面具有一定特殊性,其病死率及复发率均高于HIV阴性的内脏利什曼病患者。本文对利什曼原虫-HIV合并感染患者的临床表现、诊断和治疗进展进行综述。 相似文献
3.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
4.
目的:讨论普通变异型免疫缺陷病(common variable immunodeficiency disease,CVID)的发病机制、临床表现及治疗方法。方法:报道1例普通变异型免疫缺陷病合并肝硬化患者并复习相关文献。结果:普通变异型免疫缺陷病是临床少见病,易误诊,病因不清,临床表现复杂,部分患者病程中可出现肝功能异常,甚至并发肝硬化。结论:临床反复感染的患者应考虑CVID的可能,须进一步作血浆免疫球蛋白的检测确诊。对已经确诊患者定期补充静脉丙种球蛋白,同时还应定期检查肝功能。 相似文献
5.
6.
A. A. Vo M. Toyoda A. Peng S. Bunnapradist M. Lukovsky S. C. Jordan 《American journal of transplantation》2006,6(10):2384-2390
Here we retrospectively examine the efficacy of two antibody induction regimens using Zenapax or Thymoglobulin in patients with positive complement-dependent cytotoxicity crossmatches (CDC-CMXs) desensitized with IVIG (intravenous immunoglobulin). Between January 1999 and March 2005, 97 patients with (+) CDC-CMXs received kidney transplants (43 deceased donors/54 living donors). All patients received at least 2 g/kg IVIG (maximum four doses) until an acceptable CMX was obtained. Patients were divided into two groups: 1. IVIG + Zenapax (n = 58), 2. IVIG + Thymoglobulin (n = 39). A total of 94% of patients in Group 1 and 84% in G2 have at least 2 years of follow up. Patient and graft survival was 96%/84% in Group 1 and 100%/90% in Group 2, p = NS. The number and severity of AR episodes were similar (36% Group 1 vs. 31% Group 2, p = NS) as was the incidence of C4d (+) antibody-mediated rejection (AMR) (Banff Grade II/III) (22% Group 1 vs. 21% Group 2). Mean serum creatinines (SCrs) at 24 months were similar (Group 1: 1.4 +/- 0.7 vs. G2: 1.5 +/- 0.7 mg/dL). Induction therapy with Zenapax or Thymoglobulin results in excellent patient, graft survival and graft function at 2 years. There was no increased risk of viral infections or malignancies with either agent. Neither agent was effective in reducing the incidence of AMR. 相似文献
7.
Irina Elovaara Ilkka Seppl Esko Kinnunen Hannu Laaksovirta 《Journal of neuroimmunology》1991,35(1-3):65-77
The presence of free immunoglobulin light chains (FLCs) in the cerebrospinal fluid (CSF) and sera of patients with human immunodeficiency virus-1 (HIV-1) infection, multiple sclerosis (MS), and neurologically healthy control individuals was investigated by paying special attention to ensure that only truly free light chains would be detected. The FLCs were extracted by specifically binding them to Sepharose-coupled anti-FLC monoclonal antibodies, and thereafter they were electrophoresed and immunoblotted with monoclonal antibodies to both light chain (LC) isotypes. A frequent occurrence of kappa and lambda FLCs was found in both CSF and sera of HIV-1 infected patients. In HIV-1 infection and in MS, the frequency of FLCs of the CSF was equal. In healthy controls, only occasional weak FLCs were observed in either CSF or serum. FLC bands of the CSF from patients with HIV-1 infection tended to be more intensive than those of the appropriately diluted sera. Both intrathecal synthesis of FLCs and their transudation from sera through the impaired blood-brain barrier (BBB) may contribute to this. Increasing severity of general HIV-1 infection was accompanied by an increase of FLC intensity in sera. A qualitative demonstration of FLC in the CSF may be meaningful only in the absence of altered BBB function. 相似文献
8.
中药提高AIDS患者免疫功能的研究 总被引:2,自引:2,他引:0
艾滋病在我国已进入快速传播期,积极开展中医药治疗艾滋病研究具有重要意义。中医学理论认为,艾滋病的病因不外“正虚”、“邪侵”两端。即邪毒入侵和精亏气虚;病机为脏腑虚损和气血津液失常;临床和实验研究已发现一批治疗艾滋病有效的中药,作用机理主要是抑制艾滋病病毒,调整免疫功能和控制机会性感染;其中以增强患者免疫功能最具有中医特色。 相似文献
9.
We correlated MRI features with histopathological findings in an HIV-positive patient with vacuolar myelopathy. On MRI symmetrical
nonenhancing high-signal areas in the posterior columns on T2-weighted images result from extensive vacuolation visible on
histological sections.
Received: 18 November 1997 Accepted: 23 March 1997 相似文献
10.
Leon G. Epstein 《Pediatrics international》1998,40(2):107-111
Abstract Human immunodeficiency virus (HIV)-l neuropathogenesis can be divided into three important components: (i) virus entry into the nervous system; (ii) the role of viral proteins and/or cellular products in neural tissue damage; and (iii) the mechanisms of neuronal injury/death. Both blood derived macrophages or trafficking HIV-1 infected T-lymphocytes have been implicated in viral entry to the central nervous system (CNS). The major cell type harboring productive HIV-1 infection in the nervous system is the perivascular macrophage/ microglia. The HIV-1 infection of brain astrocytes, restricted to the expression of regulatory gene products, may cause astrocyte dysfunction and contribute to neuronal injury or to disruption of the blood-brain barrier (BBB). Studies of cerebrospinal fluid and postmortem tissues reveal chronic inflammation/immune activation in the nervous system during the later stages of HIV-1 infection associated with disruption of BBB integrity. Blood-brain barrier damage may underlie the white matter pallor described in HIV-1 infection and could result in further entry into the CNS of toxic viral or cellular products, or additional HIV-1 infected cells. The HIV infected and activated macrophages/microglia produce excessive amounts of pro-inflammatory cytokines, including tumor necrosis factor alpha, and platelet activating factor. These products are directly toxic to human neurons in vitro. The HIV-1 envelope glycoprotein, gp 120 may stimulate the release of toxic factors from brain macrophages. Blocking N-methyl-D-aspartate (NMDA; or AMPA) glutamate receptors can antagonize candidate toxins of both viral and cellular origin. It has been postulated that (weak) excitotoxicity leads to oxidative stress in neurons and ultimately to apoptosis. Neuronal apoptosis occurs in the brains of both children and adults with HIV-1 infection. This understanding of HIV neuropathogenesis implies that therapeutic strategies should include: (i) anti-retroviral medications to decrease systemic and CNS virus load, and possibly to prevent perinatal transmission of HIV; (ii) anti-inflammatory compounds to decrease the chronic immune activation in microglia and allow the restoration of BBB integrity; and (iii) neuroprotective compounds to reduce neuronal injury and apoptotic death. 相似文献